Literature DB >> 14521332

Are the 2-isomers of the drug rimantadine active anti-influenza A agents?

Grigoris Zoidis1, Nicolas Kolocouris, George B Foscolos, Antonios Kolocouris, George Fytas, P Karayannis, Elizaveta Padalko, Johan Neyts, Erik De Clercq.   

Abstract

There is a lack of information in the medical chemistry literature concerning the anti-influenza A activity of the drug rimantadine's 2-isomer (2-rimantadine). We now present results showing that, although 2-adamantanamine (2-amantadine) 3 is only moderately active, some 2-rimantadine analogues are effective anti-influenza A virus agents in vitro. The 2-rimantadine analogues and their spirocyclobutane and spirocyclopentane congeners were synthesized through interesting routes. The 2-rimantadine analogues were 2-4 times more potent than rimantadine 2 against influenza virus A H2N2 strain; their spirocyclobutane congeners proved equally active to rimantadine 2. Two compounds exhibited a similar activity and one of the compounds was was fourfold more potent than rimantadine 2 against H3N2 strain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14521332     DOI: 10.1177/095632020301400305

Source DB:  PubMed          Journal:  Antivir Chem Chemother        ISSN: 0956-3202


  9 in total

1.  Influence of an additional amino group on the potency of aminoadamantanes against influenza virus A. II - Synthesis of spiropiperazines and in vitro activity against influenza A H3N2 virus.

Authors:  Christos Fytas; Antonios Kolocouris; George Fytas; Grigoris Zoidis; Charalampos Valmas; Christopher F Basler
Journal:  Bioorg Chem       Date:  2010-09-21       Impact factor: 5.275

Review 2.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

3.  Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus.

Authors:  María D Duque; Chunlong Ma; Eva Torres; Jun Wang; Lieve Naesens; Jordi Juárez-Jiménez; Pelayo Camps; F Javier Luque; William F DeGrado; Robert A Lamb; Lawrence H Pinto; Santiago Vázquez
Journal:  J Med Chem       Date:  2011-04-05       Impact factor: 7.446

4.  Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus.

Authors:  Marta Barniol-Xicota; Sabrina Gazzarrini; Eva Torres; Yanmei Hu; Jun Wang; Lieve Naesens; Anna Moroni; Santiago Vázquez
Journal:  J Med Chem       Date:  2017-04-24       Impact factor: 7.446

5.  Potentiation of azole antifungals by 2-adamantanamine.

Authors:  Michael D Lafleur; Lingmei Sun; Ida Lister; John Keating; Andre Nantel; Lisa Long; Mahmoud Ghannoum; Jeffrey North; Richard E Lee; Ken Coleman; Thomas Dahl; Kim Lewis
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

6.  Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.

Authors:  Roger G Ptak; Philippe A Gallay; Dirk Jochmans; Andrew P Halestrap; Urs T Ruegg; Luke A Pallansch; Michael D Bobardt; Marie-Pierre de Béthune; Johan Neyts; Erik De Clercq; Jean-Maurice Dumont; Pietro Scalfaro; Kamel Besseghir; Roland M Wenger; Brigitte Rosenwirth
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

Review 7.  Antiviral agents active against influenza A viruses.

Authors:  Erik De Clercq
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694

8.  A combined study on structures and vibrational spectra of the antiviral rimantadine using SQMFF and DFT calculations.

Authors:  Maximiliano A Iramain; José Ruiz Hidalgo; Tom Sundius; Silvia Antonia Brandán
Journal:  Heliyon       Date:  2022-08-06

9.  Synthesis and pharmacological evaluation of (2-oxaadamant-1-yl)amines.

Authors:  María D Duque; Pelayo Camps; Lenuta Profire; Silvia Montaner; Santiago Vázquez; Francesc X Sureda; Jordi Mallol; Marta López-Querol; Lieve Naesens; Erik De Clercq; S Radhika Prathalingam; John M Kelly
Journal:  Bioorg Med Chem       Date:  2009-02-13       Impact factor: 3.641

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.